Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

.

St Jude Medical

(

STJ

) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.3%. By the end of trading, St Jude Medical rose 59 cents (1.8%) to $34.28 on heavy volume. Throughout the day, 9.1 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 3.7 million shares. The stock ranged in a price between $33.87-$35.06 after having opened the day at $34.75 as compared to the previous trading day's close of $33.69. Other companies within the Health Care sector that increased today were:

Peregrine Pharmaceuticals

(

PPHM

), up 29.3%,

Cormedix

(

CRMD

), up 26.7%,

SunLink Health Systems

(

SSY

), up 16.7%, and

Telik

(

TELK

), up 13.8%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in four segments: Cardiac Rhythm Management, Cardiovascular, Atrial Fibrillation, and Neuromodulation. St Jude Medical has a market cap of $10.14 billion and is part of the health services industry. The company has a P/E ratio of 13.8, below the S&P 500 P/E ratio of 17.7. Shares are down 4.1% year to date as of the close of trading on Thursday. Currently there are 13 analysts that rate St Jude Medical a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates St Jude Medical as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front,

USMD Holdings

(

USMD

), down 23%,

Supernus Pharmaceuticals

(

SUPN

), down 18.7%,

Alimera

(

ALIM

), down 14.2%, and

ImmuCell Corporation

(

ICCC

), down 9.2%, were all laggards within the health care sector with

Questcor Pharmaceuticals

(

QCOR

) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade

.

null